Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KANDOVA - a Two-Part Phase Ib/IIa Study to Evaluate the Safety and Tolerability of KAND567, in Combination with Carboplatin Therapy, and to Determine the Recommended Phase II Dose (RPIID) of KAND567: an Open-Label, Multicenter Dose Escalation Study with an Expansion Cohort in Women with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Next Previous
X
Search
Trial Profile

KANDOVA - a Two-Part Phase Ib/IIa Study to Evaluate the Safety and Tolerability of KAND567, in Combination with Carboplatin Therapy, and to Determine the Recommended Phase II Dose (RPIID) of KAND567: an Open-Label, Multicenter Dose Escalation Study with an Expansion Cohort in Women with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; KAND-567 (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms kandova
  • Sponsors Kancera

    • Most Recent Events

    • 18 Dec 2024 Protocol was amended to add a primary endpoint -Determine the Recommended Phase II Dose (RPIID) of KAND567 in combination with carboplatin, The SRC is also mandated to modify the dose levels within the dose range (125 to 625 mg BID), as well as the schedule to maintain subject safety and best serve the objectives of the study.
    • 18 Dec 2024 Planned End Date changed from 30 Jun 2024 to 1 Mar 2025.
    • 18 Dec 2024 Planned primary completion date changed from 30 Jun 2024 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top